Last updated on

Pancreas
Research Hotspot & Journal Scope - Adenocarcinoma


Pancreas - DOI: 10.1097/MPA.0000000000001231
Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis

Jordan M Cloyd · Hsiang-Chun Chen · Xuemei Wang · Ching-Wei D Tzeng · Michael P Kim · Thomas A Aloia · Jean-Nicolas Vauthey · Jeffrey E Lee · Matthew H G Katz ·

Medicine
PDF
Pancreas - DOI: 10.1097/MPA.0000000000001195
Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma

Joni Leppänen · Ville Lindholm · Joel Isohookana · Kirsi-Maria Haapasaari · Peeter Karihtala · Petri P. Lehenkari · Juha Saarnio · Joonas H. Kauppila · Tuomo J. Karttunen · Olli Helminen · Heikki Huhta ·

Biology Medicine
PDF
Pancreas - DOI: 10.1097/MPA.0000000000001404
Relationship Between Radiomics and Risk of Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma

Yun Bian · Shiwei Guo · Hui Jiang · Suizhi Gao · Chenwei Shao · Kai Cao · Xu Fang · Jing Li · Li Wang · Wenda Hua · Jianming Zheng · Gang Jin · Jianping Lu ·

Medicine Biology
PDF
Pancreas - DOI: 10.1097/MPA.0000000000001261
Desmoplasia in Lymph Node Metastasis of Pancreatic Adenocarcinoma Reveals Activation of Cancer-Associated Fibroblasts Pattern and T-helper 2 Immune Cell Infiltration

Eran Nizri · Shoshi Bar-David · Asaf Aizic · Neta Sternbach · Guy Lahat · Ido Wolf · Joseph Klausner ·

Medicine
PDF
Pancreas - DOI: 10.1097/MPA.0000000000001363
Surgical and Oncological Outcomes of Laparoscopic Versus Open Pancreaticoduodenectomy in Patients With Pancreatic Duct Adenocarcinoma

Zi Yin · Zhixiang Jian · Baohua Hou · Haosheng Jin ·

Medicine
PDF

We report on the feasibility and clinical value of ctDNA testing in patients with gastric cancers in a real time clinical context by reporting data on cohort of patients with gastric cancers (including those with gastroesophageal junction adenocarcinomas) treated at our institution.

Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. [10.21037/JGO.2019.01.14]


Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations.

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations [10.2147/OTT.S213928]


This patient represents a rare case of long-term survival of recurrent gastric adenocarcinoma successfully treated with surgery despite particularly poor prognosis.

Long-term survival after surgical resection of locoregional gastric adenocarcinoma recurrence — a case report [10.5603/OCP.2019.0006]


0003) demonstrated an attenuated effect on the aggressiveness of the colorectal tumor, with a reduction in the count of Aberrant Crypt foci; and a lower percentage of malignant neoplastic lesions in the GTumor+Prob (40% low grade tubular adenoma, 40% carcinoma in situ, 20% low grade adenocarcinoma) and GTumor+5-FU+Prob (40% low grade tubular adenoma and 60% carcinoma in situ).

Probiotic supplementation attenuates the aggressiveness of chemically induced colorectal tumor in rats. [10.1016/j.lfs.2019.116895]


BACKGROUND Epidermal growth factor receptor (EGFR) and hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathways, which promote tumour growth and proliferation, are often deregulated in advanced gastroesophageal adenocarcinomas.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. [10.1016/j.ejca.2019.04.020]


Highly Related Keywords from Adenocarcinoma

Research Hotspot

Pancreas

Research Hotspot
Pancreas Related Journals

Popular Journals